# Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

> **NCT05798533** · PHASE1 · UNKNOWN · sponsor: **BGI, China** · enrollment: 6 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** Neo-T
- **COMBINATION_PRODUCT:** Toripalimab
- **COMBINATION_PRODUCT:** Tislelizumab

## Key facts

- **NCT ID:** NCT05798533
- **Lead sponsor:** BGI, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-10
- **Primary completion:** 2023-09
- **Final completion:** 2024-09
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2023-07-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05798533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05798533, "Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05798533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*